Skip to content

13F-HR filed by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC filed this 13F-HR for the quarter ended 2015-12-31, filed 2016-02-12, with 29 holding rows worth $290,298,000.

Accession
0001144204-16-081239
Filed
2016-02-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2015

A holdings report, 31 entries on the cover page, a total value of $290,298,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $290,298,000 with VALUE read as thousands by filing date, 13F file number 028-16573. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MIRATI THERAPEUTICS INC60468T105COM1,258,055$39,755,000thousands by filing date
AMICUS THERAPEUTICS INC03152W109COM3,515,611$34,101,000thousands by filing date
Lion Biotechnologies53619R102COM3,187,607$24,608,000thousands by filing date
LA JOLLA PHARMACEUTICAL CO503459604COM PAR $.0001 2784,199$21,173,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM503,007$19,406,000thousands by filing date
PERNIX THERAPEUTICS HOLDINGS71426V108COM5,144,916$15,178,000thousands by filing date
DERMIRA INC24983L104COM354,950$12,285,000thousands by filing date
TELIGENT INC NEW87960W104COM1,373,294$12,222,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM1,260,809$11,738,000thousands by filing date
SORRENTO THERAPEUTICS INC83587F202COMMON STOCK1,146,579$9,987,000thousands by filing date
AGENUS INC00847G705COM NEW2,199,137$9,984,000thousands by filing date
ONCOTHYREON INC682324108COM4,119,072$9,144,000thousands by filing date
NEURODERM LTDM74231107ORD SHS520,022$8,866,000thousands by filing date
NANTKWEST INC63016Q102COM599,287$8,828,000thousands by filing date
AEGERION PHARMACEUTICALS INC00767E102COM733,125$7,405,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM127,000$7,184,000thousands by filing date
AXOVANT SCIENCES LTDG0750W104COM307,070$5,536,000thousands by filing date
VERACYTE INC COM92337F107Stock741,353$5,338,000thousands by filing date
EGALET CORP28226B104COM432,606$4,767,000thousands by filing date
Innocoll45780Q103SPONDS ADR501,722$4,164,000thousands by filing date
FORTRESS BIOTECH INC34960Q109COM1,337,869$3,733,000thousands by filing date
TRILLIUM THERAPEUTICS INC COM NEW89620X506Stock253,697$3,199,000thousands by filing date
VERICEL CORP92346J108COM1,135,120$2,929,000thousands by filing date
TONIX PHARMACEUTICALS HOLDING890260201COM NEW340,300$2,610,000thousands by filing date
Accelerate Diagnostics00430H102COM112,885$2,426,000thousands by filing date
Alliqua BioMedical Inc019621200COM NEW839,100$1,796,000thousands by filing date
CELLECTIS ADS15117K103COM35,000$1,086,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM47,300$626,000thousands by filing datecall
CATALYST14888D109COM71,500$224,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001144204-16-081239this filing2016-02-12acceptance time not in the bulk data set